



Pfizer New Zealand Limited
Level 1, Suite 1.4, Building B
8 Nugent Street, Grafton, Auckland 1023
PO Box 3998, Shortland Street, Auckland, New Zealand 1140
Tel: 09 354 3065 Fax: 09 374 7630

Pfizer New Zealand Limited

Friday, 9 August 2019

Business Law Team
Ministry of Business, Innovation & Employment (MBIE)
Wellington

Re: Discussion Paper on Intellectual Property Laws Amendment Bill

Dear MBIE Business Law Team,

As one of the world's leading research based pharmaceutical companies, Pfizer views a strong and stable intellectual property system as critical to fostering pharmaceutical innovation, investment, productivity and competitiveness. A robust IP system underpins the development of innovative medicines and vaccines that enable people to live longer, healthier and more productive lives.

Pfizer has had the opportunity to review the submission prepared by Medicines New Zealand on the discussion paper published by the Ministry of Business, Innovation and Employment (MBIE), which sought written submissions in respect of issues that may be included in the Intellectual Property Laws Amendment Bill (the IP Amendment Bill).

Pfizer supports the responses made in the MNZ submission that relate to the matters raised in that discussion paper.

Pfizer also believes the introduction of patent term extensions would strengthen New Zealand's IP framework and we would welcome the opportunity to provide detailed submissions to the MBIE, which could include a comparative analysis of international systems and an assessment of the various methods of calculation of the term of such extensions.

Yours sincerely,



Melissa McGregor
Managing Director
Pfizer Australia and New Zealand